cytochrome p450-2c19

Efavirenz (DMP 266) 是一种人类免疫缺陷病毒 1 非核苷类似物逆转录酶抑制剂。它也是一种野生型HIV-1 RT 抑制剂，Ki 为 2.93 nM，有效抑制 HIV-1 复制，IC95为 1.5 nM。

Luliconazole (NND 502) 是一种咪唑类抗生素，具有广谱抗真菌活性。它可研究皮肤感染。

(R)-Omeprazole is the inactive isomer of omeprazole , a gastric proton-pump inhibitor. A stereoselective hydroxylation of (R)-omeprazole is mediated primarily by cytochrome P450 (CYP) 2C19, whereas CYP3A4 favors sulfoxidation of the active (S)-enantiomer . (R)-Omeprazole has been shown to act as a reversible direct-acting and metabolism-dependent inhibitor of CYP2C19 in pooled human liver microsomes (IC50 = 8.1 μM).

5-hydroxy Omeprazole is a major metabolite of omeprazole , an inhibitor of the gastric H+ K+-ATPase pump.[1] 5-hydroxy Omeprazole is produced from omeprazole by the action of cytochrome P450 (CYP) isoform 2C19, a monooxygenase. [2][3] CYP2C19 polymorphisms significantly influence the metabolism of omeprazole, and individuals may be classified as homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers.[1]

LKY-047, a derivative of Decursin, is a highly effective and specific reversible competitive inhibitor of cytochrome P45022J2 (CYP2J2), with an IC 50 value of 1.7 μM. LKY-047 does not display inhibitory activity against other human P450 enzymes including CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.